Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q2 2022 · 10-Q
Revenue—
Net Income-$2.98M-$2.98MN/M vs Q2 2021 EPS Diluted-$0.10-$0.10N/M vs Q2 2021 Operating Income-$3,014,000N/M Operating Cash Flowderived-$2,786,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 15, 2022 · 46 d after period end